
Ana M Sartori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8989332/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An Open-label Randomized Controlled Parallel-group Pilot Study Comparing the Immunogenicity of a Standard-, Double-, and Booster-dose Regimens of the 2014 Seasonal Trivalent Inactivated Influenza Vaccine in Kidney Transplant Recipients. Transplantation, 2022, 106, 210-220.	0.5	5
2	Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases. Vaccine: X, 2022, 10, 100131.	0.9	3
3	Human Papillomavirus (HPV) seroprevalence, cervical HPV prevalence, genotype distribution and cytological lesions in solid organ transplant recipients and immunocompetent women in Sao Paulo, Brazil. PLoS ONE, 2022, 17, e0262724.	1.1	5
4	Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 1036-1043.	0.5	30
5	Impact of polio vaccines (oral polio vaccine - OPV or inactivated polio vaccine - IPV) on rotavirus vaccine-associated intussusception. Human Vaccines and Immunotherapeutics, 2022, 18, 1-7.	1.4	1
6	Adverse events following yellow fever vaccination in immunocompromised persons. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2021, 63, e13.	0.5	8
7	Systematic review and meta-analysis of HPV vaccination in women with systemic lupus erythematosus (SLE). Expert Review of Vaccines, 2021, 20, 309-318.	2.0	5
8	Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity. Lupus, 2021, 30, 1915-1922.	0.8	3
9	Clinical profile and mortality in patients with T. cruzi/HIV co-infection from the multicenter data base of the "Network for healthcare and study of Trypanosoma cruzi/HIV co-infection and other immunosuppression conditions― PLoS Neglected Tropical Diseases, 2021, 15, e0009809.	1.3	12
10	Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil. Vaccine, 2020, 38, 46-53.	1.7	3
11	Awareness of Inadvertent Use of Yellow Fever Vaccine Among Recipients of Renal Transplant. Transplantation Proceedings, 2020, 52, 1291-1293.	0.3	3
12	Economic evaluation of adolescents and adults' pertussis vaccination: A systematic review of current strategies. Human Vaccines and Immunotherapeutics, 2019, 15, 14-27.	1.4	19
13	Low tetanus-diphtheria-acellular pertussis (Tdap) vaccine coverage among healthcare workers in a quaternary university hospital in São Paulo, Brazil: need for continuous surveillance and implementation of active strategies. Brazilian Journal of Infectious Diseases, 2019, 23, 231-236.	0.3	6
14	Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report. Vaccine, 2019, 37, 5137-5146.	1.7	35
15	Spatial analysis of pneumococcal meningitis in São Paulo in the pre- and post-immunization era. Revista De Saude Publica, 2019, 53, 59.	0.7	0
16	Systematic review of health economic evaluation studies of dengue vaccines. Vaccine, 2019, 37, 2298-2310.	1.7	12
17	A systematic review of adult tetanus-diphtheria-acellular (Tdap) coverage among healthcare workers. Vaccine, 2019, 37, 1030-1037.	1.7	15

Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December) Tj ETQq0 0 0 rgBI5/Overlo&k 10 Tf 50 18

ANA M SARTORI

#	Article	IF	CITATIONS
19	Single-dose varicella vaccine effectiveness in Brazil: A case-control study. Vaccine, 2018, 36, 479-483.	1.7	19
20	Challenges of interpreting epidemiologic surveillance pertussis data with changing diagnostic and immunization practices: the case of the state of São Paulo, Brazil. BMC Infectious Diseases, 2018, 18, 126.	1.3	16
21	Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60†years of age or older. Vaccine, 2018, 36, 2510-2522.	1.7	10
22	Syphilis in pregnancy, congenital syphilis, and factors associated with mother-to-child transmission in Itapeva, São Paulo, 2010 to 2014 Revista Da Sociedade Brasileira De Medicina Tropical, 2018, 51, 819-826.	0.4	4
23	Extensive local reaction after vaccination. International Journal of Infectious Diseases, 2018, 73, 364.	1.5	ο
24	Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2018, 60, e37.	0.5	4
25	A formação de profissionais de saúde para atuação na rede de frio e salas de vacinas. Cadernos De Saude Publica, 2018, 34, .	0.4	Ο
26	A systematic review of health economic evaluations of vaccines in Brazil. Human Vaccines and Immunotherapeutics, 2017, 13, 1454-1465.	1.4	7
27	Vaccines are different: A systematic review of budget impact analyses of vaccines. Vaccine, 2017, 35, 2781-2793.	1.7	8
28	Long-term protection after hepatitis B vaccination in people living with HIV. Vaccine, 2017, 35, 4155-4161.	1.7	7
29	Systematic Review Of Economic Evaluation Studies For Dengue Vaccine: How Valid Are The Results?. Value in Health, 2017, 20, A932.	0.1	1
30	Role of T. cruzi exposure in the pattern of T cell cytokines among chronically infected HIV and Chagas disease patients. Clinics, 2017, 72, 652-660.	0.6	2
31	Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2017, 59, e2.	0.5	19
32	Evaluation of Reference Centers for Special Immunobiologicals implementation. Revista De Saude Publica, 2016, 50, 58.	0.7	2
33	CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 189-195.	0.9	33
34	Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil. Vaccine, 2016, 34, 1531-1539.	1.7	22
35	CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. PLoS Neglected Tropical Diseases, 2016, 10, e0005219.	1.3	50
36	Healthcare resource utilization and costs of outpatient follow-up after liver transplantation in a university hospital in São Paulo, Brazil: cost description study. Sao Paulo Medical Journal, 2015, 133, 171-178.	0.4	4

ANA M SARTORI

#	Article	IF	CITATIONS
37	Methods and challenges for the health impact assessment of vaccination programs in Latin America. Revista De Saude Publica, 2015, 49, .	0.7	5
38	Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil. Clinics, 2015, 70, 289-295.	0.6	16
39	Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil. Vaccine, 2015, 33, A135-A142.	1.7	18
40	Polio inactivated vaccine costs into routine childhood immunization in Brazil. Revista De Saude Publica, 2015, 49, 8.	0.7	7
41	Costing Dengue Fever Cases and Outbreaks: Recommendations from a Costing Dengue Working Group in the Americas. Value in Health Regional Issues, 2015, 8, 80-91.	0.5	14
42	Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil. PLoS ONE, 2015, 10, e0130217.	1.1	18
43	Modelling the Force of Infection for Hepatitis A in an Urban Population-Based Survey: A Comparison of Transmission Patterns in Brazilian Macro-Regions. PLoS ONE, 2014, 9, e94622.	1.1	30
44	Introduction of universal human papillomavirus vaccination of girls aged 11 years to the National Immunization Program in Brazil: a cost-effectiveness analysis. Lancet, The, 2014, 384, S19.	6.3	0
45	Estimating health service utilization for treatment of pneumococcal disease: The case of Brazil. Vaccine, 2013, 31, C63-C71.	1.7	5
46	Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more. Human Vaccines and Immunotherapeutics, 2013, 9, 277-282.	1.4	21
47	Spontaneous reporting of adverse events following pandemic influenza A (H1N1) immunization in a reference center in the State of Sao Paulo, Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2013, 46, 348-351.	0.4	2
48	Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil. Journal of Epidemiology and Community Health, 2012, 66, 210-217.	2.0	35
49	TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology, 2012, 51, 2091-2098.	0.9	56
50	Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: Regional analyses according to the endemic context. Vaccine, 2012, 30, 7489-7497.	1.7	32
51	PIH18 Regional Cost-Effectiveness Analysis of Universal Childhood Hepatitis a Vaccination in Brazil. Value in Health, 2012, 15, A194.	0.1	Ο
52	Hepatitis B revaccination for healthcare workers who are anti-HBs-negative after receiving a primary vaccination series. Revista Da Sociedade Brasileira De Medicina Tropical, 2012, 45, 639-642.	0.4	6
53	Contributions from the systematic review of economic evaluations: the case of childhood hepatitis A vaccination in Brazil. Cadernos De Saude Publica, 2012, 28, 211-228.	0.4	8
54	Measuring Adherence to Antiretroviral Treatment: The Role of Pharmacy Records of Drug Withdrawals. AIDS and Behavior, 2012, 16, 1482-1490.	1.4	18

ANA M SARTORI

#	Article	IF	CITATIONS
55	A importância dos métodos de custeio e valoração nas avaliações econômicas em saúde: repercussõ sobre os resultados de avaliação da vacina antimeningocÃ3cica C. Physis, 2012, 22, 641-658.	^{2S} 0.1	0
56	Cost-Effectiveness Analysis of a Universal Infant Immunization Program with Meningococcal C Conjugate Vaccine in Brazil. Value in Health, 2011, 14, 1019-1027.	0.1	18
57	Hospitalization rates for pneumococcal disease in Brazil, 2004 - 2006. Revista De Saude Publica, 2011, 45, 539-547.	0.7	19
58	Real-Time PCR in HIV/Trypanosoma cruzi Coinfection with and without Chagas Disease Reactivation: Association with HIV Viral Load and CD4+ Level. PLoS Neglected Tropical Diseases, 2011, 5, e1277.	1.3	97
59	PIN52 COST ESTIMATES IN THE ECONOMIC EVALUATIONS OF VACCINATION PROGRAMMES: THE CASES OF ROTAVIRUS AND VARICELLA IN BRAZIL. Value in Health, 2009, 12, A427.	0.1	2
60	Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine, 2008, 26, 6281-6291.	1.7	41
61	Intervention to Increase Influenza Vaccination Rates Among Healthcare Workers in a Tertiary Teaching Hospital in Brazil. Infection Control and Hospital Epidemiology, 2008, 29, 285-286.	1.0	14
62	Rotavirus morbidity and mortality in children in Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2008, 23, 92-100.	0.6	37
63	Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2008, 23, 221-230.	0.6	36
64	Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Annals of Tropical Medicine and Parasitology, 2007, 101, 31-50.	1.6	181
65	A review of the varicella vaccine in immunocompromised individuals. International Journal of Infectious Diseases, 2004, 8, 259-270.	1.5	65
66	Trypanosoma cruziParasitemia in Chronic Chagas Disease: Comparison between Human Immunodeficiency Virus (HIV)–Positive and HIVâ€Negative Patients. Journal of Infectious Diseases, 2002, 186, 872-875.	1.9	91
67	Exacerbation of HIV viral load simultaneous with asymptomatic reactivation of chronic Chagas' disease American Journal of Tropical Medicine and Hygiene, 2002, 67, 521-523.	0.6	49
68	Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Brazilian Journal of Infectious Diseases, 2001, 5, 332-8.	0.3	26
69	Reactivation of Chagas disease manifested by skin lesions in a patient with AIDS. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 631-632.	0.7	45
70	Followâ€up of 18 Patients with Human Immunodeficiency Virus Infection and Chronic Chagas' Disease, with Reactivation of Chagas' Disease Causing Cardiac Disease in Three Patients. Clinical Infectious Diseases, 1998, 26, 177-179.	2.9	74
71	Acompanhamento clÃnico e laboratorial de indivÃduos com doença de Chagas e infectados pelo vÃrus da imunodeficiência humana. Revista Da Sociedade Brasileira De Medicina Tropical, 1998, 31, 587-588.	0.4	2
72	Reactivation of Chagas' disease in a human immunodeficiency virus-infected patient leading to severe heart disease with a late positive direct microscopic examination of the blood American Journal of Tropical Medicine and Hygiene, 1998, 59, 784-786.	0.6	59

#	Article	IF	CITATIONS
73	Simultaneous Occurrence of Acute Myocarditis and Reactivated Chagas' Disease in a Patient with AIDS. Clinical Infectious Diseases, 1995, 21, 1297-1299.	2.9	65
74	Risk factors for reduction in adherence to protective measures following COVID-19 vaccination and vaccine perceptions among healthcare workers, in Sao Paulo, Brazil. Infection Control and Hospital Epidemiology, 0, , 1-41.	1.0	0